Shire Plc(Bolsa Mexicana De Valores (Mexican Stock Exchange) : SHPG)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -0.25% | 158.92 | 0.7% | $1251.69m | |
| PFE | Pfizer Inc. | 0.06% | 33.55 | 0.9% | $1146.07m | |
| MRK | Merck & Co., Inc. | 0.57% | 72.79 | 0.7% | $838.26m | |
| BMY | Bristol-Myers Squibb Co. | -0.63% | 61.24 | 1.0% | $812.59m | |
| ABBV | AbbVie, Inc. | -0.54% | 107.83 | 1.9% | $755.30m | |
| LLY | Eli Lilly & Co. | -1.04% | 204.32 | 1.1% | $671.62m | |
| AZN | AstraZeneca Plc | -0.75% | 47.73 | 1.2% | $504.47m | |
| GSK | GlaxoSmithKline Plc | 1.07% | 34.09 | 0.2% | $276.75m | |
| NVS | Novartis AG | 1.85% | 88.17 | 0.2% | $176.09m | |
| SNY | Sanofi | 0.07% | 45.94 | 0.2% | $161.63m | |
| VTRS | Viatris, Inc. | -2.92% | 14.29 | 0.0% | $145.44m | |
| VERU | Veru, Inc. | -2.78% | 14.01 | 0.0% | $116.99m | |
| CVAC | CureVac NV | -3.47% | 92.84 | 0.0% | $90.70m | |
| NVO | Novo Nordisk A/S | 0.01% | 72.65 | 0.1% | $89.13m | |
| RPRX | Royalty Pharma Plc | -2.25% | 46.95 | 0.2% | $85.82m |
Company Profile
Shire is the leading global biotechnology company focused on serving people with rare diseases. They have a global sales and marketing infrastructure with a broad portfolio of products and direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. At Shire, the company ground everything they do in their purpose of enabling people with life altering conditions to lead better lives. The company's patient and customer focused culture encourages employees to embrace innovation and challenge the status quo through respectful and inclusive engagement with colleagues. Honesty and transparency are inherent in all that we do as we work with a high sense of urgency to become a leading global biotech delivering innovative therapies to patients with rare diseases and other specialty conditions. We foster an environment where leaders are positive, accountable, results driven and great people managers. Our employees own their development in partnership with their manager, understand and leverage their strengths, bring their whole selves to work, and like the leaders they are expected to eventually become, share the essential traits of positive, accountable and results driven. Our non-hierarchical structure and clear reporting lines enable quick decision making, nimble execution and the opportunity for employees to enjoy the work and grow to their fullest potential. The company is committed to recruit, develop and retain top talent who take a responsible and ethical approach to all that we do and who want to make a difference in the lives of patients across the globe.